Adaptive T cells regulate disease tolerance in human malaria

Immunity to severe malaria is acquired quickly, operates independently of pathogen load and represents a highly effective form of disease tolerance. The mechanism that underpins tolerance in human malaria remains unknown. We developed a re-challenge model of falciparum malaria in which healthy naive adult volunteers were infected three times over a 12-month period to track the development of disease tolerance in real-time. We found that parasitaemia triggered a hardwired emergency myeloid response that led to systemic inflammation, pyrexia and hallmark symptoms of clinical malaria across the first three infections of life. In contrast, CD4+ T cell activation was quickly modified to reduce the number and diversity of effector cells upon re-challenge. Crucially, this did not silence critical helper T cell functions but instead prevented the generation of cytotoxic effectors associated with autoinflammatory disease. Tolerised hosts were thus able to prevent collateral tissue damage and injury. Host control of T cell activation can therefore be established after a single infection and in the absence of anti-parasite immunity. And furthermore, this rapid host adaptation can protect vital organs to minimise the harm caused by systemic inflammation and sequestration.


27
The epidemiology of human malaria clearly shows that immunity develops in two distinct phases. 28 First, individuals acquire protection against severe life-threatening disease and in areas of high 29 transmission this occurs very quickly (often before 12-months of age) (1-4). Then after many years 30 of exposure protection against clinical malaria is established, which promotes the transition to 31 asymptomatic infection (usually in adolescence) (5). This temporal dissociation between clinical 32 immunity and immunity to severe malaria has led to the assumption that they must be underpinned 33 by different mechanisms of host defense. In agreement, clinical immunity coincides with control of 34 parasite burden (and is therefore supported by mechanisms of host resistance) whereas immunity 35 to severe malaria is acquired independently of pathogen load and is a form of disease tolerance (1). 36 One leading hypothesis suggests that broadly neutralising antibodies that recognise variant surface 37 antigens associated with severe malaria (such as group A/DC8 PfEMP1) could prevent severe 38 disease without affecting total pathogen load (2). In this scenario, immunity to severe malaria would 39 depend upon the rapid production of antibodies that can specifically eliminate pathogenic variants. 40 At present, there is limited evidence that such broad cross-reactivity can be achieved or that 41 neutralising antibodies can be produced within the first year of life to inhibit cytoadherence and 42 reduce sequestration in vivo (6). The mechanism that underpins disease tolerance in human malaria 43 therefore remains unclear. 44 An alternative explanation is that the host response to infection is quickly modified to minimise the 45 harm caused by malaria parasites. It is well known that metabolic adaptations are induced during 46 the blood cycle to increase host fitness (7-9) and control of inflammation might provide an additional 47 path towards disease tolerance (10). In support of this argument, inflammation can be uncoupled 48 from parasite density in children (11) and pathogenic immune responses can be silenced to minimise 49 tissue stress and toxicity in mice (12). Importantly, host control of inflammation as a defense strategy 50 would not rule out a role for variant surface antigens in severe disease. After all, systemic 51 inflammation, tissue damage and hypoxia could create the right conditions for endothelium activation 52 and the selection of pathogenic variants (13). As such, reducing inflammation may minimise the 53 preferential expansion of parasites associated with severe malaria -this would represent a highly 54 effective route to disease tolerance that would not be influenced by parasite strain or genotype. 55 Host adaptations that are quickly established to reduce disease severity will be hard to identify in an 56 endemic setting due to the difficulty of pinpointing an infant's first infection of life. On the other hand, 57 controlled human malaria infection (CHMI) (14) offers an unparalleled opportunity to investigate 58 mechanisms of disease tolerance. Naive volunteers are inoculated with live and non-attenuated 59 parasites and their response can be tracked throughout infection and convalescence by repeated 60 sampling; pre-infection samples can be collected to provide all-important baseline measurements; 61 and the immune system is exposed to an enormous antigen load at the peak of infection (more than 62 10 7 parasites per litre of blood) (13). Crucially, adults are more susceptible to severe malaria than 63 children during a first-in-life infection (15, 16) and so we can study the most at-risk group of 64 individuals. We therefore developed a human re-challenge model of falciparum malaria to track the 65 development of disease tolerance in real-time across the first three infections of life.! 66

Malaria does not induce fast-acting mechanisms of host resistance 68
We developed a human re-challenge model of falciparum malaria in which ten healthy adult 69 volunteers were infected two times (4-months apart) by intravenous injection of infected red cells; 70 six volunteers returned for a third infection 8-months later ( figure 1A). A blood challenge model was 71 chosen because it standardises the infectious dose, prolongs the period of blood-stage infection (cf. 72 mosquito challenge) and removes liver-stage immunity as a possible confounding factor upon re-73 challenge (17, 18). Furthermore, volunteers were always inoculated with the same clonal malaria 74 parasite (3D7) to remove parasite genotype as an infection-dependent variable. Importantly, we 75 used a recently mosquito-transmitted line (< 3 blood cycles from liver egress) (19) since mosquitoes 76 have been shown to reset parasite virulence (20). Volunteers attended clinic the day before infection 77 (baseline), every 12-hours from the day after infection until diagnosis (peak of infection) and then 78 24-and 48-hours after drug treatment. These frequent visits allowed for regular blood sampling to 79 construct a detailed longitudinal time-course of each volunteer's response to the first three infections 80 of life. 81 We found that pathogen load and the parasite multiplication rate were comparable between the first, 82 second and third malaria episode (figure 1B-C and supplementary file 1). Whilst epidemiology has 83 shown that anti-parasite immunity does not develop within this time-frame (1) these data 84 nevertheless derive from an endemic setting where each infection is caused by a new parasite 85 genotype. It is remarkable then that in our study (which removes polymorphism as an obstacle to 86 immunity) we find no evidence that volunteers can limit the replication of parasites they have seen 87 previously. Epidemiology has also shown that immunity to clinical malaria is slow to develop, and in 88 most cases is not acquired until adolescence (5). In agreement, we found no significant difference 89 in the number or severity of adverse events (such as headache, fever and fatigue) between first, 90 second and third infection (figure 1D-E). Differential blood counts revealed other hallmark symptoms 91 of clinical malaria, such as lymphopenia and anaemia, were also comparable between infections 92 (figure 1F and figure 1 -supplement 1). These data thus show that healthy adult volunteers do not 93 acquire mechanisms of resistance (to reduce parasite burden) and remain susceptible to clinical 94 malaria in a homologous re-challenge model. 95

Re-challenge triggers a hardwired emergency myeloid response 96
The absence of anti-parasite immunity means that any change in the host response to re-challenge 97 must occur independently of pathogen load. Our model therefore provides the ideal setting in which 98 to investigate host adaptations that confer disease tolerance. One route to tolerance may be to 99 reduce systemic inflammation -this correlates with clinical immunity in endemic regions (11) but 100 whether it also coincides with immunity to severe disease is not known. In human challenge studies 101 the immune response detected in whole blood at the peak of infection is largely driven by activated 102 monocytes and neutrophils, which are in transit from the bone marrow (site of activation) (21) to the 103 spleen (target organ) (22). To capture this acute phase response we used whole blood  sequencing and DESeq2 to identify differentially expressed genes at diagnosis (relative to baseline) 105 in first, second and third infection. We found a remarkably similar pattern of interferon-stimulated 106 type I inflammation regardless of infection number (figure 2 -supplement 1). Furthermore, functional 107 gene enrichment analysis showed that the hierarchy of GO terms was near-identical between 108 infections ( figure 2A). This emergency myeloid response has been extensively described in naive 109 hosts infected with P. falciparum (13, 23, 24) and P. vivax (Bach et al.,under review,preprint 110 available at doi.org/10.1101/2021.03.22.21252810) but it was surprising to see no obvious change 111 upon re-challenge. Nevertheless, by analysing each infection independently it was possible that we 112 were missing important quantitative differences and we therefore performed direct pairwise 113 comparisons between first, second and third infection. Initially, we compared each pre-infection time-114 point to identify season-dependent shifts in baseline gene expression -we found zero differentially 115 expressed genes between infections (adj p < 0.05 and absolute fold change > 1.5). When we then 116 compared each diagnosis time-point to identify adaptations in the host response we again found 117 zero differentially expressed genes ( figure 2B); evidently, the first three infections of life trigger a 118 hardwired emergency response that is not influenced by season or previous exposure. 119 Nonetheless, host control of inflammation may not be transcriptionally regulated and we therefore 120 directly measured systemic inflammation at protein level using a highly multiplexed custom bead 121 array (39 plasma analytes indicative of inflammation, coagulation, oxidative stress & metabolism). 122 By analysing the concentration of each analyte through time we found many of the prototypical 123 products of monocyte and neutrophil activation (such as CXCL10, IL-1RA & MPO) were significantly 124 increased at diagnosis, together with hallmark cytokines associated with innate lymphoid cell (ILC) 125 or T cell activation (IFN" and IL-21) ( figure 2C and figure 2 -supplement 2). Surprisingly, our data 126 seemed to suggest that this response was not attenuated but enhanced upon re-challenge. To 127 directly test this hypothesis we fitted a linear mixed-effects model for each analyte, which showed 128 that the major secreted products of interferon-stimulated inflammation were significantly increased 129 in second and third (compared to first) infection ( figure 2D). Collectively, these data demonstrate 130 that P. falciparum triggers a hardwired emergency myeloid response throughout the first three 131 infections of life. And crucially, we find no evidence that systemic inflammation can be attenuated to 132 quickly establish disease tolerance. 133

Malaria uncouples T cell activation from systemic inflammation 134
Our data do not exclude the importance of minimising systemic inflammation to improve clinical 135 outcome but indicate that long-term exposure to parasites is required to restrict an inflammatory 136 myeloid response (12). These data may partially explain why immunity to clinical malaria is not 137 usually established until adolescence. So what other host adaptations could be acquired early in life 138 to promote immunity to severe disease? To answer this question we examined adaptive T cells, 139 which are inherently plastic, proliferative and long-lived, and therefore uniquely placed to quickly and 140 permanently alter the host response to infection. The acute phase response to malaria causes 141 extreme lymphopenia leading to a 30 -70% loss of circulating T cells at the peak of infection ( figure  142 1 -supplement 1). The majority of these cells are recruited to the inflamed spleen (25) and it is 143 therefore difficult to assess T cell activation and differentiation at diagnosis. Instead, we need to 144 analyse T cell activation after drug treatment when the myeloid response begins to resolve and T 145 cells return to the circulation. At this time-point, analysing T cell phenotypes in whole blood can 146 provide a direct readout of tissue-specific immune responses in human malaria. 147 Post-treatment blood samples were not available from this cohort of volunteers in their first infection 148 but were collected 6-days after drug treatment of either their second or third malaria episode . We  149  therefore had to recruit new malaria-naive controls to provide time-matched post-treatment samples  150  of first infection and switched to a cross-sectional study design with 11 volunteers infected  151  contemporaneously (3 first infection, 2 second infection and 6 third infection during the VAC063C  152 trial) (see methods and supplementary file 1). Six days after drug treatment (designated T6) 153 lymphopenia had completely resolved and there was no evidence of delayed onset anaemia ( figure  154 3A and figure 3 -supplement 1A). All other clinical symptoms of malaria (inc. fever) also resolved 155 and markers of systemic inflammation had returned almost entirely to baseline -this was observed 156 in every volunteer regardless of infection number (figure 3 -supplement 1B). It was therefore a 157 surprise to find a large transcriptional signature in whole blood at T6, which was equal in size to the 158 emergency myeloid response captured at diagnosis (figure 3 -supplement 2A). These signatures 159 did not overlap and instead the differentially expressed genes at T6 had unique functional enrichment 160 terms relating to cell cycle and nuclear division (figure 3 -supplement 2B-C). Remarkably, this 161 proliferative burst was only observed in volunteers undergoing their first infection of life (figure 3 -162 supplement 3). 163 Myeloid cells are generally terminally differentiated and do not proliferate after their release from the 164 bone marrow; it therefore seemed likely that our whole blood RNA-sequencing data were capturing 165 the return of activated T cells to the circulation. To explore this further we sorted CD4 + T cells with a 166 naive (CCR7 pos CD45RA pos ), effector / effector memory (EM) (CCR7 neg CD45RA neg ) or regulatory 167 (CD25 hi CD127 neg ) phenotype one day before challenge and six days post-treatment. Analysis of the 168 cell surface markers used for sorting revealed dramatic activation of effector / EM and regulatory 169 subsets in first infection but not reinfection (figure 3B and figure 3 -supplement 4). These data 170 suggested that T cell activation and systemic inflammation could be uncoupled in malaria. To directly 171 test this hypothesis we constructed a pearson correlation matrix and included all plasma analytes 172 that were significantly up-or downregulated at diagnosis or T6 together with the frequency of 173 activated effector and regulatory CD4 + T cells ( figure 3C). Also included were hallmark symptoms of 174 clinical malaria such as pyrexia, lymphopenia and anaemia. We found a strong and significant 175 positive correlation between markers of myeloid cell activation (inc. CXCL10, IL-1RA & TNFRII), 176 coagulation (D-Dimer) and maximum core temperature (r > 0.7 and p < 0.05). Moreover, each of 177 these features negatively correlated with lymphocyte counts and haemoglobin. In contrast, activated 178 effector and regulatory CD4 + T cells did not correlate with any feature of the acute phase response 179 (supplementary file 2). The intensity of inflammation therefore scales with clinical symptoms but does 180 not influence CD4 + T cell activation. 181

TH1 polarisation is a unique feature of first infection 182
Naive adults are highly susceptible to severe malaria (15) and our data clearly show that the unique 183 feature of their response to infection is fulminant T cell activation. To explore the transcriptional 184 landscape of activated CD4 + T cells in first infection (compared to third) we undertook RNA-185 sequencing on the naive, effector / EM and regulatory subsets that we had sorted during the 186 VAC063C trial (figure 3 -supplement 4) and used DESeq2 to identify differentially expressed genes 187 at T6 (versus baseline). As expected, cells with a naive phenotype displayed few transcriptional 188 changes upon their return to circulation; in contrast, we found almost 6000 differentially expressed 189 genes in effector / EM CD4 + T cells (adj p < 0.05 and > 1.5-fold change). Functional gene enrichment 190 analysis showed that effector cells were proliferative, metabolically reprogrammed and highly 191 activated in first infection, upregulating each of the major costimulatory and inhibitory receptors 192 required to control their fate (figure 4A and figure 4 -supplement 1). Moreover, they specifically 193 upregulated the signature chemokine receptors and transcription factors associated with TH1 194 polarisation (figure 4B). The cytokines IFN" and IL-21 were also both strongly induced, which could 195 indicate that infection stimulates double-producers (26) or that activated follicular helper T cells are 196 also released from the spleen (figure 4C). 197 In third infection IFN" and IL-21 were once again significantly upregulated at T6 together with TNF 198 and TH1-associated chemokine receptors (figure 4B-C). CD4 + T cells are thus clearly responsive to 199 re-challenge despite the lack of evidence for their activation by flow cytometry ( figure 3B). Yet There was also no evidence that effector CD4 + T cells were diverted towards a regulatory fate; for 208 example, hallmarks of TR1 differentiation (such as Eomes and IL-10) were absent (figure 4B-C). 209 An alternative explanation could be suppression by conventional regulatory CD4 + T cells yet our 210 data show that Tregs simply mirror the response of effector cells. Their activation is tightly co-211 regulated (figure 3C) and in first infection Tregs launch a transcriptional programme with remarkable 212 overlap to that of effectors (e.g. they upregulate all signature TH1 genes including T-bet) (figure 4D). 213 In contrast, we could find no transcriptional evidence of Treg activation upon re-challenge. It is well 214 established that regulatory T cells mimic the transcriptional response of the effector cells they are 215 required to regulate (27) and this phenomenon is clearly evident in naive hosts. In fact, by 216 constructing a merged gene ontology network that uses all of the differentially expressed genes 217 identified in effector / EM and regulatory CD4 + T cells we could show that Tregs do not display any 218 unique functional terms (figure 4E). We therefore conclude that regulatory T cells are redundant 219 during reinfection and that their activation is not required because there is no explosive effector 220 response to keep in check. Instead, it would seem that tolerised hosts launch a specialised adaptive 221 T cell programme that can maintain cytokine production without causing extensive activation, 222 proliferation or TH1 polarisation. Remarkably, we can identify this major shift in the host response in 223 whole blood (figure 4F) and it will therefore be possible to identify tolerised hosts in an endemic 224 setting without the need for complex cell isolation protocols. 225

Tolerance minimises effector T cell heterogeneity 226
One limitation of bulk RNA-sequencing is that it can not reveal the heterogeneity of an immune 227 response; this is particularly problematic for CD4 + T cells, which are inherently diverse and plastic. 228 Furthermore, there is very little power to detect transcriptional changes if only a small proportion of 229 cells are activated, as seemed to be the case in third infection. We therefore used mass cytometry 230 to undertake single cell analysis of T cell activation through first and third infection. Importantly, we 231 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021.
designed an antibody panel that would allow us to interrogate every T cell lineage, and examine the 232 key markers of activation, differentiation and fate (supplementary file 3). We first concatenated all 233 data (from every volunteer and time-point) and used Uniform Manifold Approximation and Projection 234 (UMAP) to visualise the phenotypic diversity of T cells across the dataset. We then used FlowSOM 235 clustering to assign each T cell to one of 49 discrete clusters (figure 5 -supplement 1). As expected 236 most of the diversity was observed within the non-naive CD4 + and CD8 + T cell subsets (figure 5A). 237 Tracking the frequency of each cluster through time then resolved dynamic changes in the T cell 238 compartment (figure 5 -supplement 2 for CD4 + T cells, supplement 3 for CD8 + T cells and 239 supplement 4 for innate-like T cells). Finally, we performed linear regression on cell count data using 240 EdgeR to identify the differentially abundant clusters at each time-point relative to baseline (FDR < 241 0.05 and absolute fold-change > 2). 242 In first infection eighteen T cell clusters increased in abundance at T6 and all had an activated 243 phenotype; these were comprised of twelve adaptive and six innate-like clusters. In third infection, 244 twelve clusters increased in abundance and not one was unique to re-challenge (all were significant 245 in first infection). Remarkably, we found that diversity was specifically reduced in the adaptive T cell 246 response with only six adaptive clusters called as significant in third infection. Moreover, of these six 247 clusters all but one was reduced in size compared to first infection (figure 5B-C). This means that 248 activated CD4 + T cells dominate the response of naive hosts to malaria whereas in tolerised hosts 249 the T cell response largely consists of innate-like cells ( figure 5D). So how do the phenotypes of 250 activated CD4 + T cells compare between infections? We observed enormous heterogeneity in first 251 infection with the expansion of nine distinct CD4 + T cell clusters. There were common traits (such as 252 expression of the activation marker CD38 and the memory marker CD45RO) and most had an 253 effector (CCR7 neg ) phenotype but many clusters displayed unusual or unexpected features (figure 254 5E). As one example, the largest pool of activated CD4 + T cells had a highly differentiated CD27 neg 255 CX3CR1 pos cytotoxic phenotype, which is usually observed in autoinflammatory conditions (not 256 infectious disease) (28, 29). Notably, the upregulation of perforin and granzyme B could be seen in 257 CD4 + T cells by RNA-sequencing ( figure 4C) and there were many other areas of concordance 258 between the datasets. Most importantly, our protein data confirmed that effector CD4 + T cells were 259 highly activated (CD28 hi PD1 hi ), TH1 polarised (T-bet hi ), proliferative (Ki67 hi ) and accompanied by the 260 activation of Foxp3 hi CD39 hi T-bet + regulatory T cells. 261 In contrast, the unusual CD4 + T cell phenotypes observed in naive hosts were essentially absent in 262 third infection and there was no expansion of activated Tregs (figure 5C). Instead, the majority of 263 expanded CD4 + T cells belonged to a single cluster with an apparently benign effector phenotype 264 (ICOS neg Ki67 neg T-bet lo Eomes neg ) (figure 5E). These cells are clearly activated (CD38 hi Bcl2 lo ) and 265 had already increased in abundance at diagnosis (figure 5 -supplement 2). A faster response may 266 indicate that these are malaria-specific memory cells. Furthermore, as the dominant activated cluster 267 these CD4 + T cells are likely to be responsible for most of the transcriptional changes in the effector 268 / EM subset in third infection, including cytokine production ( figure 5D and figure 4C). To validate 269 these phenotypic observations we used limma to model differential marker is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; Collectively, these data show that tolerance leads to a smaller and less diverse adaptive T cell 274 response. Although at first glance this may seem counterintuitive we argue that this is a more 275 proportional host response designed to support the development of humoral immunity (long-term 276 goal) whilst providing short-term protection against collateral damage. After all, it is essential to 277 prioritise host fitness when infected with a pathogen that can not be cleared and the functionally 278 diverse CD4 + T cell response triggered in naive hosts does not appear to be beneficial (there is no 279 evidence for reduced pathogen load or improved clinical outcome during a first-in-life infection in this 280 study or endemic settings (30)). Moreover, the frequency of CD38 hi CD4 + T cells in third infection is 281 not small (it is comparable to typhoid fever (31)) and effector cells have retained critical helper 282 functions (IFN" and IL-21). It therefore appears that the adaptive response of a naive host is atypical 283 leading to the activation of 20 -40% of every T cell in circulation (figure 5F) and the generation of 284 cytotoxic effectors previously associated with immune-mediated disease. 285

Controlling T cell activation protects host tissues 286
To directly test whether T cell activation in first infection could be pathological we measured 287 biomarkers of collateral tissue damage, a common histological feature of severe malaria. The blood-288 stage of infection frequently causes liver injury in naive hosts (32-34) and auto-aggressive human T 289 cells can directly kill hepatocytes through TCR-independent mechanisms (35) -we therefore 290 measured alanine aminotransferase (ALT) to provide a readout of hepatocellular death in our cohort. 291 In first infection, two out of three volunteers had abnormal ALT (more than the upper limit of the 292 reference range) when activated T cells were released from inflamed tissues at T6 ( figure 6A). This 293 was accompanied by increased gamma-glutamyl transferase (GGT) and aspartate 294 aminotransferase (AST) leading to moderate or severe adverse events in both volunteers. In 295 contrast, there was little evidence of any deviation from baseline in liver function tests after re-296 challenge. A meaningful statistical comparison between naive and tolerised hosts was not possible 297 due to the small sample size in first infection (n = 3) and we therefore performed a meta-analysis 298 using a previously published surrogate dataset (33). Specifically, we examined post-treatment ALT 299 measurements in almost 100 volunteers experiencing a first-in-life infection as part of a human 300 challenge study. Importantly, we only included CHMI trials that were directly comparable to our own 301 re-challenge study -that is to say that the same clonal parasite genotype was used (3D7 or the 302 parental NF54 line); parasites had recently been transmitted through the vector; and the same study 303 end-points were applied (treatment at around 10,000 parasites ml -1 ) ( figure 6B). Remarkably, we 304 found that the prevalence of abnormal ALT was reduced from 75% during first infection to 25% upon 305 re-challenge ( figure 6C). And in those rare cases where ALT was increased in second or third 306 infection adverse events were mild (not moderate or severe) even though pathogen load was 307 increased ( figure 6B). These data thus show that the risk of tissue damage and injury can be 308 significantly reduced in the absence of parasite control. Here then is in vivo evidence that long-lived 309 mechanisms of disease tolerance operate in human malaria and can be acquired after a single 310 infection. Moreover, protection does not require the attenuation of systemic inflammation but instead 311 coincides with host control of T cell activation.! 312 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262298 doi: medRxiv preprint

313
It has long been recognised that immunity to severe malaria is acquired early in life, offers protection 314 against all manifestations of severe disease and usually precedes clinical immunity (the transition to 315 asymptomatic infection) by more than a decade (2-5). We also know that immunity to severe malaria 316 does not require improved parasite control (1) and is thus underpinned by acquired mechanisms of 317 disease tolerance. This is an important distinction to make if we want to understand how to reduce 318 malaria mortality. Host control of inflammation could provide a rapid route to disease tolerance but 319 our data show that malaria parasites trigger a hardwired emergency myeloid response across the 320 first three infections of life. In contrast, CD4 + T cell activation is quickly modified to limit the number 321 and diversity of effector cells. Our pilot data from a re-challenge model using P. vivax shows the 322 same attenuation of CD4 + T cells after a single infection (figure 6 -supplement 1). So how is the adaptive T cell response to malaria modified so quickly and so dramatically? One 330 possibility is that infection initiates heritable epigenetic programmes that reduce T cell 331 responsiveness. Our data do not provide transcriptional evidence of anergy or exhaustion but this 332 hypothesis needs to be directly tested. An alternative explanation could be the clonal deletion of 333 activated T cells during first infection reducing the number of malaria-specific clones available for re-334 challenge. Or perhaps, tolerance requires no T cell-intrinsic modifications but an attenuation of the 335 antigen presenting capacity of the spleen. After all, hemozoin-loaded dendritic cells and 336 macrophages have a reduced capacity to stimulate T cell proliferation in vitro (37). Long-term 337 modifications to the tissue environment (12) (including the presence of malaria-specific antibodies) 338 may also impact T cell differentation and block the development of terminally differentiated 339 pathogenic effectors. Nonetheless, the activation of T-bet lo EM CD4 + T cells (and production of IFN" 340 and IL-21) may be sufficient to support the gradual acquisition of humoral immunity in tolerised hosts. 341 Perhaps then we are asking the wrong question and should instead examine how malaria can drive 342 such extensive and diverse T cell activation in a naive host. 343 One possibility is that infection leads to widespread bystander activation of CD4 + T cells that do not 344 recognise malaria antigens. These could be pre-existing memory cells, which can be activated in the 345 absence of TCR signals and costimulation (38, 39). This would certainly explain the speed, 346 magnitude and heterogeneity of T cell activation in our naive volunteers. And furthermore, it may 347 explain the increased susceptibility of adults to severe disease during a first-in-life infection (they 348 have a far larger memory pool than infants and children). Malaria may also cause activation of 349 autoreactive T cells, which would need to be quickly suppressed by activated Tregs in first infection. 350 Central tolerance (which deletes autoreactive clones in the thymus) is only partially effective and 351 there is enormous degeneracy in TCR reactivity (40). Systemic infection with a pathogen carrying 352 more than 5000 protein-coding genes may therefore lead to considerable cross-reactivity between 353 parasite and host. Indeed, hypergammaglobulinemia and autoantibody production are known 354 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; features of human malaria (41, 42). We therefore propose that bystander and cross-reactive T cells 355 may account for the majority of T cell activation in naive hosts. And because they can be activated 356 via TCR-independent or low affinity interactions (39, 43) it might be possible to specifically silence 357 their pathogenic response without impeding re-activation of high affinity malaria-specific clones. 358 Support for this idea comes from the observation that P. chabaudi triggers massive polyclonal 359 activation of CD4 + T cells in first infection but not reinfection in mice (44). 360 Importantly, we have shown that parasite species regulates T cell activation in naive hosts -P. 361 falciparum drives a bigger CD4 + T cell response with more functional diversity than P. vivax even 362 though they trigger a near-identical myeloid response ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Edinburgh, which receives financial support from NHS Research Scotland (NRS). Whole blood 381 RNAseq libraries were prepared and sequenced by Edinburgh Genomics, which is supported 382 through core grants from NERC (R8/H10/56), MRC UK (MR/K001744/1) and BBSRC 383 (BB/J004243/1). We would like to extend our thanks to the VAC063 and VAC069 clinical and 384 laboratory teams for assistance, and to all of the volunteers who participated in this study. 385 The authors have no conflict of interest to declare and the funders had no role in study design, data 406 interpretation or the decision to submit the work for publication.! 407 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ;  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint   T6  diagnosis   v313  v315  v320  v1040  v1039  v1068  v1061  v1075  v6032  v313  v315  v320  v1040  v1039  v1068  v1061  v1075  v6032  v313  v315  v320  v1040  v1039  v1068  v1061  v1075  v6032  v313  v315  v320  v1040  v1039  v1068  v1061  v1075  v6032 first infection third infection is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Volunteers signed written consent forms and consent was checked prior to each CHMI. Details of 545 volunteer recruitment, consent, inclusion/exclusion criteria and group allocation can be found in 546 Minassian et al. (47). 547 In each CHMI study, all volunteers were infected by direct intravenous inoculation of P. falciparum 548 (clone 3D7) blood-stage parasites. The inoculum was thawed and prepared under strict aseptic 549 conditions exactly as described (47, 48) and volunteers received between 452 and 857 infected red 550 cells in a total volume of 5 ml normal saline. Starting one day after infection volunteers attended 551 clinic for assessment and blood sampling every 12-hours, and parasite density was measured in 552 real time by qPCR (target gene = 18S ribosomal RNA). In VAC063A thick blood films were also 553 evaluated at each time-point by experienced microscopists and diagnosis required volunteers to fulfil 554 two out of three criteria: a positive thick blood film (one viable parasite in 200 fields) and/or qPCR 555 data showing at least 500 parasites per ml and/or symptoms consistent with malaria. In VAC063B 556 and C microscopy was removed as a diagnostic tool to reduce the number of volunteers diagnosed 557 prematurely without impacting volunteer safety. The new criteria for diagnosis were: asymptomatic 558 with any available qPCR result above 10,000 parasites per ml or symptomatic with any available 559 qPCR data above 5000 parasites per ml. At diagnosis volunteers were treated with artemether and 560 lumefantrine (Riamet) except in cases where its use was contraindicated and atovaquone and 561 proguanil (Malarone) were given instead. In our analysis, we refer to the blood-draw immediately 562 before drug-treatment as the diagnosis time-point. 563 Clinical symptoms of malaria (pyrexia, malaise, fatigue, arthralgia, back pain, headache, myalgia, 564 chills, rigor, sweats, headache, nausea, vomiting and diarrhoea) were either recorded by the 565 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262298 doi: medRxiv preprint volunteers on diary cards or during clinic visits. All symptoms were recorded as adverse events and 566 assigned a severity score: 0 -absent; 1 -transient or mild discomfort (no medical intervention 567 required); 2 -mild to moderate limitation in activity (no or minimal medical intervention required); 3 -568 severe limitation in activity requiring assistance (may require medical intervention). Pyrexia was 569 scored as follows: absent (≤ 37.5°C), mild (37.6 -38.2°C), moderate (38.3 -38.9°C) and severe (≥ 570 39°C). In addition, full blood counts and blood chemistry were evaluated at the Churchill and John 571 Radcliffe Hospital in Oxford providing 5-part differential white cell counts and quantification of 572 electrolytes, urea, creatinine, bilirubin, alanine aminotransferase (ALT), alkaline phosphatase (ALP) 573 and albumin. 574

Meta-analysis of liver injury 575
A surrogate dataset from Reuling et al. (33) was used to assess the risk of liver injury during a first-576 in-life infection compared to re-challenge. We extracted data from every CHMI study that used the 577 3D7 P. falciparum clone (or its parental NF54 line), initiated infection via mosquito bite or direct blood 578 challenge and that had a treatment threshold based on thick smear positivity (estimated to be at 579 least 5,000 parasites per ml). This produced data for 95 volunteers across 7 CHMI studies. Notably, 580 Reuling et al. used longitudinal data to show that liver function test (LFT) abnormalities peaked up 581 to 6-days post-treatment in line with our own T6 time-point. And furthermore, in every CHMI study 582 (including our own) LFT abnormalities were graded using the same adaptation of the WHO adverse 583 event grading system. An LFT reading > 1.0 but < 2.5 times the upper limit of normal was graded as 584 mild; a reading > 2.5 but < 5.0 times the upper limit was graded moderate; and a reading > 5.0 the 585 upper limit was graded severe. For ALT, the upper limit of normal was 35 or 45 units per litre for 586 female and male volunteers, respectively. Data from the 95 volunteers in Reuling et al. and the 3 587 primary controls in our VAC063C study were pooled for analysis and we calculated a weighted peak 588 parasite density across the entire cohort by using a, the mean number of parasites per ml and b, the 589 number of volunteers in each of the 8 CHMI studies. To statistically test whether an abnormal ALT 590 reading was more prevalent in the 98 volunteers experiencing their first malaria infection compared 591 to the 8 volunteers undergoing re-challenge (either second or third infection) we used Barnard's test, 592 which examines the association of two independent categorical variables in a 2x2 contingency table. 593 A p value below 0.05 was considered significant. 594

Processing whole blood for RNA and plasma 595
Venous blood was drawn into K2EDTA-coated vacutainers (Becton Dickinson #367835). To preserve 596 RNA for whole blood transcriptome analysis 1 ml of blood was mixed thoroughly with 2 ml Tempus 597 reagent (ThermoFisher #4342792) and samples were stored at -80°C. Note that no more than 2-598 hours passed between blood draw and RNA preservation. To obtain platelet-depleted plasma 3 ml 599 of blood was divided into two 2 ml Eppendorf tubes and centrifuged at 1,000 xg for 10-minutes at 600 4°C to pellet cellular components. Working on ice, plasma was then carefully transferred to a new 601 tube and spun again -this time at 2,000 xg for 15-minutes at 4°C to pellet platelets. Cell-free, 602 platelet-depleted plasma was then aliquoted into new tubes, snap frozen on dry ice and stored at -603 80°C. 604 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  CD127 pos CCR7 neg CD45RA neg ) and regulatory (CD3 pos CD4 pos CD25 hi CD127 neg ). T cells were sorted 661 directly into RNAse free sterile 1.5 ml screw cap tubes (ThermoFisher #11529924) containing 1 ml 662 Trizol Reagent (ThermoFisher #15596026). Tubes were incubated for 5-minutes at room 663 temperature and stored at -80°C. At the same time, we sorted naive T cells into flow buffer and 664 reacquired them to check sort purity, which was above 95% for every sample analysed in this study. 665 Flow data acquired during sorting was analysed using FlowJo v9 software. 666 CD4 + T cell RNA-sequencing 667 RNA was extracted using a modified phenol-chloroform protocol (58) with 1-Bromo-3-chloropropane 668 (Sigma-Aldrich #B62404) and Isopropanol (Acros Organics #423835000 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; environment (v3.6) and differential gene expression analyses (pairwise group comparisons) 689 performed using functions within the DESeq2 package (52). lfcShrink was applied to the output of 690 each comparison (type normal). Lists of differentially expressed transcripts were filtered by removing 691 all non-coding transcripts and retaining only those with adj p < 0.05 and fold-change > 1.5. Multiple 692 transcripts annotated to the same gene were consolidated by keeping the transcript with the highest 693 absolute fold-change. Heatmaps and circular stacked bar plots were generated using the ggplot2 694 package. 695 assigned a unique colour and a network was then generated using an edge-weighted spring-704 embedded layout based on kappa score. Groups were named by the leading GO term (lowest adj p 705 with min. GO level 5 or 6). Merged networks were constructed by inputting two lists of differentially 706 expressed genes. For each GO term information on what fraction of associated genes were derived 707 from each list was retained. Any GO term containing > 60% associated genes from a single list was 708 considered to be enriched in that group, otherwise GO terms were considered to be shared. 709

Multiplexed plasma analyte analysis 710
The concentration of 39 analytes was measured in plasma samples collected at baseline, during 711 infection, diagnosis, 6-days after drug treatment (T6) and at a memory timepoint (28-or 45-days 712 post-challenge). Plasma was thawed on ice and centrifuged at 1000 xg for 1-minute to remove 713 potential protein aggregates. We customised 4 LEGENDplex panels (BioLegend) and performed 714 each assay on filter plates according to the manufacturer's instructions. Samples and standards 715 were acquired on a LSRFortessa flow cytometer (BD Biosciences). FCS files were processed using 716 LEGENDplex software (version 7.1), which automatically interpolates a standard curve using the 717 plate-specific standards and calculates analyte concentrations for each sample. All samples from 718 v1040 were excluded after failing QC and downstream data analysis was performed in R v3.6. To 719 determine which plasma analytes varied significantly through time we used the lme4 package to fit 720 a linear mixed-effects model for each analyte. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; function and adjusted for multiple testing (Benjamini and Hochberg). Only analytes that were 731 significant in both second and third infection (versus first infection) are shown (adj p < 0.05 and fold-732 change > 1.5). 733

Pearson correlation analysis 734
The fold-change of each significant plasma analyte (shown in figure 3 -supplement 1B), the number 735 of circulating lymphocytes and haemoglobin concentration were calculated at diagnosis or T6 736 (relative to baseline) according to their largest absolute fold-change. The percentage of activated 737 effector and regulatory CD4 + T cells, the maximum parasite density and maximum core temperature 738 (at any time-point up to 48-hours post-treatment) were also included in the analysis. All data were 739 log2 transformed and Pearson correlation was performed using the corrplot function. Correlation 740 coefficients were then used for hierarchical clustering by Euclidean distance. 741

CyTOF sample acquisition 742
Venous blood was collected in K2EDTA-coated vacutainers, stabilised within 30-minutes of blood 743 draw in whole blood preservation buffer (Cytodelics #hWBCS002) and stored at -80°C. For antibody 744 staining, samples were thawed at 37°C in a water bath, fixed for 15-minutes and red blood cells 745 lysed using the whole blood preservation kit (Cytodelics #hC002). Cells were permeabilised with 746 Maxpar barcode perm buffer (Fluidigm #201057) and each sample was barcoded using Cell-ID 20-747 plex palladium barcodes (Fluidigm #201060). Samples were then pooled and stained with our T cell 748 focussed surface antibody panel (see supplementary file 3) for 30-minutes. Following washing, cells 749 were fixed and permeabilised with the Maxpar nuclear antigen staining buffer set (Fluidigm #201063) 750 and incubated with the nuclear antibody mix for 45-minutes. After washing, cells were fixed for 10-751 minutes in 1.6% formaldehyde diluted in PBS (ThermoFisher #28906). Cells were then washed 752 again, resuspended at a concentration of 3 x 10 6 cells per ml in 72.5 nM Cell-ID Intercalator Ir solution 753 (Fluidigm #201192A) and stored overnight at 4°C. Samples were acquired the next day on a freshly 754 tuned Helios mass cytometer (Fluidigm, acquisition rate 300-500 events/second) using the WB 755 injector and 10% EQ Four Element Calibration Beads (140Ce, 151Eu, 165Ho, and 175Lu; Fluidigm 756 #201078). 757

CyTOF data analysis 758
The Fluidigm CyTOF software (version 6.7) generated FCS files, which were normalised (61) and 759 debarcoded (62)  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; were considered for embedding. UMAP coordinates were then exported for visualisation using 770 ggplot2 (53). FlowSOM (67) uses self-organising maps (SOM) to efficiently categorise cytometry 771 data into non-overlapping cell populations and was performed using CATALYST (63) (default 772 parameters, target: 100 clusters, 50 metaclusters). After manual inspection we merged two 773 phenotypically similar clusters to avoid overclustering (68) and ended up with 49 discrete T cell 774 clusters. The R/Bioconductor package ComplexHeatmap (69) was used to visualise T cell 775 phenotypes; the arcsine transfomed signal intensity of each marker was independently scaled using 776 a 0-1 transformation across all 49 clusters. 777 For differential cluster abundance analysis we used the workflow laid out by Nowicka et al. (70). 778 FlowSOM cluster cell counts were modelled linearly with time-point as a dependent categorical 779 variable and volunteer as a fixed effect using the diffcyt (71) implementation of edgeR (72). The 780 edgeR functions automatically normalise cluster counts for the total number of cells and improve 781 statistical power by sharing information on cluster count variance between clusters. Pairwise 782 comparisons were performed relative to baseline, and clusters with an FDR < 0.05 and absolute fold 783 change > 2 were deemed to vary significantly through time. We assessed differential cluster 784 abundance independently for volunteers receiving either their first or third infection. We also 785 assessed whether marker expression significantly varies through time in the major T cell subsets. 786 To do this, we merged clusters of the same lineage according to their expression of CD4, CD8, 787 CD56, Vδ2 and V#7.2. CD4 + and CD8 + T cells were then split into naive, effector, effector memory 788 and central memory T cells based on their expression of the markers CD45RA, CD45RO, CD57 and 789 CCR7. All regulatory T cells (CD25 hi CD127 neg ) were merged into a single cluster as were all double 790 negative, gamma delta, MAIT and NK T cells. Linear models derived from the limma package, which 791 is optimised for continuous data, were then used to independently assess differential marker 792 expression relative to baseline using pairwise comparisons with moderated t-tests; a shift in median 793 expression of at least 10% and an FDR < 0.05 were required for significance. Results were visualised 794 using ComplexHeatmap (69) with row-wise z-score transformed marker intensities shown for each 795 subset. 796 To analyse the T cell response to Plasmodium vivax data from two previously conducted clinical 797 trials were used. In VAC069A six healthy malaria-naive adults were recruited to test the infectivity 798 and safety of a new cryopreserved stabilate containing a novel clone of P. vivax (PvW1); this 799 stabilate had been carefully prepared for use in CHMI by blood challenge (Minassian et al.,under 800 review). In VAC069B three volunteers returned for a homologus re-challenge (8-months after 801 VAC069A) and two additional malaria-naive adults received their first infection with PvW1. In both 802 CHMI trials treatment was initiated once two diagnostic conditions were fulfilled: parasitaemia above 803 5,000 parasite genome copies per ml; parasitaemia above 10,000 genome copies per ml; positive 804 thick blood smear and/or symptoms consistent with malaria. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262298 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  diagnosis  c8  c6  baseline  diagnosis  c8  c6  baseline  diagnosis  c8  c6  baseline  diagnosis  c8  c6  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; Figure 2 -supplement 2 | Systemic inflammation peaks at diagnosis. Mixed-effects modelling was 832 used to identify plasma analytes that vary significantly at diagnosis across the entire dataset (all 833 volunteers and all infections). Kenward Roger approximation was used to calculate p values and 834 multiple test correction was performed using the Benjamini-Hochberg method (*adj p < 0.05, **adj p 835 < 0.005, ***adj p < 0.0005). Box (median and IQR) and whisker (1.5x upper or lower IQR) plots are 836 shown with outliers as dots. n = 9 (first and second infection) and 5 (third infection). v1040 was 837 excluded from plasma analysis because all samples failed QC. 838 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ;  diagnosis  c8  c6  baseline  T6  diagnosis  c8  c6  baseline  T6  diagnosis  c8  c6  baseline  T6  diagnosis  c8  c6  baseline  T6 figure three -supplement 1 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262298 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; Figure 3 -supplement 3 | The acute phase response is followed by a signature of cell proliferation 862 in naive hosts. Whole blood RNA-sequencing was used to identify differentially expressed genes at 863 diagnosis and T6 (versus baseline) during first and third infection (adj p < 0.05 and > 1.5 fold-864 change). The log2 fold-change of key genes associated with each phase of the cell cycle is shown. 865 n = 3 (first infection) and 6 (third infection). 866 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; Figure 3 -supplement 4 | Gating strategy for sorting CD4 + T cells during the VAC063C trial. CD4 + 867 T cell subsets were sorted ex vivo (within 2-hours of blood draw) into TRIzol for downstream  sequencing -cells with a naive, effector / effector memory (EM) and regulatory phenotype were gated 869 as shown at baseline and T6. Note that we did not use CD38 for sorting but subsequently used this 870 marker to assess the level of activation within each subset at both time-points. 871 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ;  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; assigned manually using activation, lineage and memory markers to broadly categorise each T cell 898 cluster; when more than one cluster was placed into the same category (e.g. activated EM CD4) 899 clusters were given an accessory label to highlight their unique phenotype or property (e.g. T-bet lo ). 900 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021.  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262298 doi: medRxiv preprint cluster is shown as a proportion of all CD45 pos CD3 pos T cells at each time-point. Clusters that were 909 significantly increased during infection are shown first followed by clusters that were significantly 910 decreased (ordered by size, big to small). Thereafter, clusters that did not vary significantly through 911 time are displayed (ordered by size, small to big). Box (median and IQR) and whisker (1.5x upper or 912 lower IQR) plots are shown (with outliers as dots) and significance (FDR < 0.05 and > 2 fold-change) 913 is indicated by a coloured box. n = 3 (first infection) and 6 (third infection). 914 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021.  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; Every cluster is shown as a proportion of all CD45 pos CD3 pos T cells at each time-point. Clusters that 916 were significantly increased during infection are shown first followed by clusters that were 917 significantly decreased (ordered by size, big to small). Thereafter, clusters that did not vary 918 significantly through time are displayed (ordered by size, small to big). Box (median and IQR) and 919 whisker (1.5x upper or lower IQR) plots are shown (with outliers as dots) and significance (FDR < 920 0.05 and > 2 fold-change) is indicated by a coloured box. n = 3 (first infection) and 6 (third infection). 921 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021.  v313  v6032  v1075  v1068  v1061  v1040  v1039  v320  v315  v313  v6032  v1075  v1068  v1061  v1040  v1039  v320  v315  v313  v6032  v1075  v1068  v1061  v1040  v1039  v320  v315  v313  v6032  v1075  v1068  v1061  v1040  v1039  v320  v315   baseline  memory  T6  diagnosis   first  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; Figure 5 -supplement 5 | Differential marker expression reveals attenuation of the adaptive T cell 922 response to re-challenge. We assessed whether marker expression significantly varies through time 923 in all major T cell subsets. First, T cell clusters belonging to the same lineage were merged and then 924 CD4 + and CD8 + T cells were split into naive, effector, effector memory (EM) and central memory 925 (CM) subsets. Next, linear models were used to independently assess differential marker expression 926 in each subset at each time-point (relative to baseline); a shift in median expression of at least 10% 927 and an FDR < 0.05 were required for significance. Shown are all subset/marker pairs that were called 928 as significant at T6 and data are presented as row-wise z-score marker intensities. Colour codes to 929 the left of the heatmap indicate whether markers were differentially expressed during first infection, 930 third infection or both infections. 931 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262298 doi: medRxiv preprint   v313   v1075  v1068  v1061  v1040  v1039  v320  v315  v6032  v313  v1075  v1068  v1061  v1040  v1039  v320  v315  v6032  v313  v1075  v1068  v1061  v1040  v1039  v320  v315  v6032  v313  v1075  v1068  v1061  v1040  v1039  v320  v315  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262298 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262298 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262298 doi: medRxiv preprint Figure 6 -supplement 1 | Plasmodium vivax induces tolerance after a single infection. Six healthy 936 malaria-naive adults were infected with P. vivax (clone PvW1) by direct blood challenge and three 937 volunteers returned for a homologous re-challenge 8-months later. These CHMI trials were called 938 VAC069A and VAC069B, respectively. Two additional healthy malaria-naive volunteers were 939 infected with PvW1 (for the first time) during VAC069B. In both trials, whole blood was preserved 940 within 30-minutes of blood draw at baseline, diagnosis and 6-days post-treatment (T6) -samples 941 were is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 24, 2021. ;